Login to Your Account



Compugen CEO: 'This is Only the Start'

Compugen Rockets on $540M Bayer Immunotherapy Alliance

By Jennifer Boggs
Managing Editor

Tuesday, August 6, 2013

Shares of Compugen Ltd. jumped 44.5 percent Monday on news of a potential $540 million deal with Bayer Healthcare to develop antibody drugs for cancer immunotherapy, marking the Israeli firm's first substantial revenue-sharing drug development collaboration.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription